Turn on cookies to sign in
Signing in saves your progress to your Curie account. We can only do that with cookies on — turn them on to continue.

A new study shows that combining tumor treating fields (TTFields) with standard chemotherapy doesn't just extend survival in pancreatic cancer — it also meaningfully improves patients' quality of life and delays pain. Published in JAMA Network Open, the phase 3 PANOVA-3 trial found that TTFields reduced digestive symptoms and pushed back the need for opioids compared to chemo alone.
For patients battling unresectable, locally advanced pancreatic adenocarcinoma, treatment options are limited and quality of life often takes a hit. But a new secondary analysis of the phase 3 PANOVA-3 trial, published in JAMA Network Open, offers some encouraging news: adding tumor treating fields (TTFields) to gemcitabine and nab-paclitaxel not only extends survival but also preserves — and even improves — how patients feel day to day.
Across a 26-month follow-up, patients in the TTFields arm reported better digestive symptoms, less pain, and reduced pancreatic pain starting as early as 2 months into treatment. They also took longer to need opioids for pain management, a meaningful win for patient comfort.
By the Numbers
Why it matters: Pancreatic cancer is notoriously difficult to treat, and quality of life is a critical concern. These findings suggest TTFields could be a practice-changing addition to standard chemotherapy — improving not just how long patients live, but how well they live.